node1 | node2 | node1 accession | node2 accession | node1 annotation | node2 annotation | score |
ERG1 | ERG11 | YGR175C | YHR007C | Squalene epoxidase; catalyzes the epoxidation of squalene to 2,3-oxidosqualene; plays an essential role in the ergosterol-biosynthesis pathway and is the specific target of the antifungal drug terbinafine; human SQLE functionally complements the lethality of the erg1 null mutation. | Lanosterol 14-alpha-demethylase; catalyzes C-14 demethylation of lanosterol to form 4,4''-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway; transcriptionally down-regulated when ergosterol is in excess; member of cytochrome P450 family; associated and coordinately regulated with the P450 reductase Ncp1p; human CYP51A1 functionally complements the lethality of the erg11 null mutation. | 0.999 |
ERG1 | ERG20 | YGR175C | YJL167W | Squalene epoxidase; catalyzes the epoxidation of squalene to 2,3-oxidosqualene; plays an essential role in the ergosterol-biosynthesis pathway and is the specific target of the antifungal drug terbinafine; human SQLE functionally complements the lethality of the erg1 null mutation. | Farnesyl pyrophosphate synthetase; has both dimethylallyltranstransferase and geranyltranstransferase activities; catalyzes the formation of C15 farnesyl pyrophosphate units for isoprenoid and sterol biosynthesis. | 0.962 |
ERG1 | ERG25 | YGR175C | YGR060W | Squalene epoxidase; catalyzes the epoxidation of squalene to 2,3-oxidosqualene; plays an essential role in the ergosterol-biosynthesis pathway and is the specific target of the antifungal drug terbinafine; human SQLE functionally complements the lethality of the erg1 null mutation. | Methylsterol monooxygenase; C-4 methyl sterol oxidase; catalyzes the first of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; mutants accumulate the sterol intermediate 4,4-dimethylzymosterol; human MSMO1 functionally complements the growth defect caused by repression of ERG25 expression. | 0.999 |
ERG1 | ERG26 | YGR175C | YGL001C | Squalene epoxidase; catalyzes the epoxidation of squalene to 2,3-oxidosqualene; plays an essential role in the ergosterol-biosynthesis pathway and is the specific target of the antifungal drug terbinafine; human SQLE functionally complements the lethality of the erg1 null mutation. | Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating; C-3 sterol dehydrogenase; catalyzes the second of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; human homolog NSDHL implicated in CK syndrome, and can complement yeast null mutant; molecular target of natural product and antifungal compound FR171456. | 0.999 |
ERG1 | ERG27 | YGR175C | YLR100W | Squalene epoxidase; catalyzes the epoxidation of squalene to 2,3-oxidosqualene; plays an essential role in the ergosterol-biosynthesis pathway and is the specific target of the antifungal drug terbinafine; human SQLE functionally complements the lethality of the erg1 null mutation. | 3-keto sterol reductase; catalyzes the last of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; mutants are sterol auxotrophs; mutation is functionally complemented by human HSD17B7; Belongs to the short-chain dehydrogenases/reductases (SDR) family. ERG27 subfamily. | 0.971 |
ERG1 | ERG28 | YGR175C | YER044C | Squalene epoxidase; catalyzes the epoxidation of squalene to 2,3-oxidosqualene; plays an essential role in the ergosterol-biosynthesis pathway and is the specific target of the antifungal drug terbinafine; human SQLE functionally complements the lethality of the erg1 null mutation. | Ergosterol biosynthetic protein 28; Endoplasmic reticulum membrane protein; may facilitate protein-protein interactions between the Erg26p dehydrogenase and the Erg27p 3-ketoreductase and/or tether these enzymes to the ER, also interacts with Erg6p. | 0.941 |
ERG1 | ERG3 | YGR175C | YLR056W | Squalene epoxidase; catalyzes the epoxidation of squalene to 2,3-oxidosqualene; plays an essential role in the ergosterol-biosynthesis pathway and is the specific target of the antifungal drug terbinafine; human SQLE functionally complements the lethality of the erg1 null mutation. | Delta(7)-sterol 5(6)-desaturase; C-5 sterol desaturase; glycoprotein that catalyzes the introduction of a C-5(6) double bond into episterol, a precursor in ergosterol biosynthesis; transcriptionally down-regulated when ergosterol is in excess; mutants are viable, but cannot grow on non-fermentable carbon sources; substrate of HRD ubiquitin ligase; mutation is functionally complemented by human SC5D. | 0.978 |
ERG1 | ERG6 | YGR175C | YML008C | Squalene epoxidase; catalyzes the epoxidation of squalene to 2,3-oxidosqualene; plays an essential role in the ergosterol-biosynthesis pathway and is the specific target of the antifungal drug terbinafine; human SQLE functionally complements the lethality of the erg1 null mutation. | Delta(24)-sterol C-methyltransferase; converts zymosterol to fecosterol in the ergosterol biosynthetic pathway by methylating position C-24; localized to lipid particles, the plasma membrane-associated endoplasmic reticulum, and the mitochondrial outer membrane; Belongs to the class I-like SAM-binding methyltransferase superfamily. Erg6/SMT family. | 0.965 |
ERG1 | ERG7 | YGR175C | YHR072W | Squalene epoxidase; catalyzes the epoxidation of squalene to 2,3-oxidosqualene; plays an essential role in the ergosterol-biosynthesis pathway and is the specific target of the antifungal drug terbinafine; human SQLE functionally complements the lethality of the erg1 null mutation. | Lanosterol synthase; an essential enzyme that catalyzes the cyclization of squalene 2,3-epoxide, a step in ergosterol biosynthesis; human LSS functionally complements the lethality of the erg7 null mutation; Belongs to the terpene cyclase/mutase family. | 0.999 |
ERG1 | ERG9 | YGR175C | YHR190W | Squalene epoxidase; catalyzes the epoxidation of squalene to 2,3-oxidosqualene; plays an essential role in the ergosterol-biosynthesis pathway and is the specific target of the antifungal drug terbinafine; human SQLE functionally complements the lethality of the erg1 null mutation. | Squalene synthase; Farnesyl-diphosphate farnesyl transferase (squalene synthase); joins two farnesyl pyrophosphate moieties to form squalene in the sterol biosynthesis pathway. | 0.999 |
ERG11 | ERG1 | YHR007C | YGR175C | Lanosterol 14-alpha-demethylase; catalyzes C-14 demethylation of lanosterol to form 4,4''-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway; transcriptionally down-regulated when ergosterol is in excess; member of cytochrome P450 family; associated and coordinately regulated with the P450 reductase Ncp1p; human CYP51A1 functionally complements the lethality of the erg11 null mutation. | Squalene epoxidase; catalyzes the epoxidation of squalene to 2,3-oxidosqualene; plays an essential role in the ergosterol-biosynthesis pathway and is the specific target of the antifungal drug terbinafine; human SQLE functionally complements the lethality of the erg1 null mutation. | 0.999 |
ERG11 | ERG20 | YHR007C | YJL167W | Lanosterol 14-alpha-demethylase; catalyzes C-14 demethylation of lanosterol to form 4,4''-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway; transcriptionally down-regulated when ergosterol is in excess; member of cytochrome P450 family; associated and coordinately regulated with the P450 reductase Ncp1p; human CYP51A1 functionally complements the lethality of the erg11 null mutation. | Farnesyl pyrophosphate synthetase; has both dimethylallyltranstransferase and geranyltranstransferase activities; catalyzes the formation of C15 farnesyl pyrophosphate units for isoprenoid and sterol biosynthesis. | 0.939 |
ERG11 | ERG25 | YHR007C | YGR060W | Lanosterol 14-alpha-demethylase; catalyzes C-14 demethylation of lanosterol to form 4,4''-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway; transcriptionally down-regulated when ergosterol is in excess; member of cytochrome P450 family; associated and coordinately regulated with the P450 reductase Ncp1p; human CYP51A1 functionally complements the lethality of the erg11 null mutation. | Methylsterol monooxygenase; C-4 methyl sterol oxidase; catalyzes the first of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; mutants accumulate the sterol intermediate 4,4-dimethylzymosterol; human MSMO1 functionally complements the growth defect caused by repression of ERG25 expression. | 0.999 |
ERG11 | ERG26 | YHR007C | YGL001C | Lanosterol 14-alpha-demethylase; catalyzes C-14 demethylation of lanosterol to form 4,4''-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway; transcriptionally down-regulated when ergosterol is in excess; member of cytochrome P450 family; associated and coordinately regulated with the P450 reductase Ncp1p; human CYP51A1 functionally complements the lethality of the erg11 null mutation. | Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating; C-3 sterol dehydrogenase; catalyzes the second of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; human homolog NSDHL implicated in CK syndrome, and can complement yeast null mutant; molecular target of natural product and antifungal compound FR171456. | 0.999 |
ERG11 | ERG27 | YHR007C | YLR100W | Lanosterol 14-alpha-demethylase; catalyzes C-14 demethylation of lanosterol to form 4,4''-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway; transcriptionally down-regulated when ergosterol is in excess; member of cytochrome P450 family; associated and coordinately regulated with the P450 reductase Ncp1p; human CYP51A1 functionally complements the lethality of the erg11 null mutation. | 3-keto sterol reductase; catalyzes the last of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; mutants are sterol auxotrophs; mutation is functionally complemented by human HSD17B7; Belongs to the short-chain dehydrogenases/reductases (SDR) family. ERG27 subfamily. | 0.999 |
ERG11 | ERG28 | YHR007C | YER044C | Lanosterol 14-alpha-demethylase; catalyzes C-14 demethylation of lanosterol to form 4,4''-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway; transcriptionally down-regulated when ergosterol is in excess; member of cytochrome P450 family; associated and coordinately regulated with the P450 reductase Ncp1p; human CYP51A1 functionally complements the lethality of the erg11 null mutation. | Ergosterol biosynthetic protein 28; Endoplasmic reticulum membrane protein; may facilitate protein-protein interactions between the Erg26p dehydrogenase and the Erg27p 3-ketoreductase and/or tether these enzymes to the ER, also interacts with Erg6p. | 0.999 |
ERG11 | ERG3 | YHR007C | YLR056W | Lanosterol 14-alpha-demethylase; catalyzes C-14 demethylation of lanosterol to form 4,4''-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway; transcriptionally down-regulated when ergosterol is in excess; member of cytochrome P450 family; associated and coordinately regulated with the P450 reductase Ncp1p; human CYP51A1 functionally complements the lethality of the erg11 null mutation. | Delta(7)-sterol 5(6)-desaturase; C-5 sterol desaturase; glycoprotein that catalyzes the introduction of a C-5(6) double bond into episterol, a precursor in ergosterol biosynthesis; transcriptionally down-regulated when ergosterol is in excess; mutants are viable, but cannot grow on non-fermentable carbon sources; substrate of HRD ubiquitin ligase; mutation is functionally complemented by human SC5D. | 0.999 |
ERG11 | ERG6 | YHR007C | YML008C | Lanosterol 14-alpha-demethylase; catalyzes C-14 demethylation of lanosterol to form 4,4''-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway; transcriptionally down-regulated when ergosterol is in excess; member of cytochrome P450 family; associated and coordinately regulated with the P450 reductase Ncp1p; human CYP51A1 functionally complements the lethality of the erg11 null mutation. | Delta(24)-sterol C-methyltransferase; converts zymosterol to fecosterol in the ergosterol biosynthetic pathway by methylating position C-24; localized to lipid particles, the plasma membrane-associated endoplasmic reticulum, and the mitochondrial outer membrane; Belongs to the class I-like SAM-binding methyltransferase superfamily. Erg6/SMT family. | 0.999 |
ERG11 | ERG7 | YHR007C | YHR072W | Lanosterol 14-alpha-demethylase; catalyzes C-14 demethylation of lanosterol to form 4,4''-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway; transcriptionally down-regulated when ergosterol is in excess; member of cytochrome P450 family; associated and coordinately regulated with the P450 reductase Ncp1p; human CYP51A1 functionally complements the lethality of the erg11 null mutation. | Lanosterol synthase; an essential enzyme that catalyzes the cyclization of squalene 2,3-epoxide, a step in ergosterol biosynthesis; human LSS functionally complements the lethality of the erg7 null mutation; Belongs to the terpene cyclase/mutase family. | 0.999 |
ERG11 | ERG9 | YHR007C | YHR190W | Lanosterol 14-alpha-demethylase; catalyzes C-14 demethylation of lanosterol to form 4,4''-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway; transcriptionally down-regulated when ergosterol is in excess; member of cytochrome P450 family; associated and coordinately regulated with the P450 reductase Ncp1p; human CYP51A1 functionally complements the lethality of the erg11 null mutation. | Squalene synthase; Farnesyl-diphosphate farnesyl transferase (squalene synthase); joins two farnesyl pyrophosphate moieties to form squalene in the sterol biosynthesis pathway. | 0.999 |